[-] Show simple item record

dc.contributor.authorLavoie, Brian F.eng
dc.contributor.authorSheldon, Ian M.eng
dc.coverage.spatialUnited Stateseng
dc.date.issued2000eng
dc.description.abstractComparative advantage based on resource endowments cannot explain United States (U.S.) leadership in biotechnology. Sources of heterogeneity within the process of research and development (R&D) investment, such as international differences in the maximum per-period rate of investment and regulatory uncertainty, offer a plausible explanation that can be incorporated into a real options approach to investment.eng
dc.description.bibrefIncludes bibliographical referenceseng
dc.identifier.citationAgBioForum 3(1) 2000: 47-52.eng
dc.identifier.issn1522-936Xeng
dc.identifier.urihttp://hdl.handle.net/10355/1171
dc.languageEnglisheng
dc.publisherAgBioForumeng
dc.relation.ispartofcollectionAgBioForum, vol. 3, no. 1 (2000)eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
dc.source.urihttp://www.agbioforum.missouri.edu/v3n1/v3n1a07-lavoie.htmeng
dc.subjectresearch and development (R&D)eng
dc.subjectcomparative advantageeng
dc.subject.lcshReal options (Finance)eng
dc.subject.lcshBiotechnology -- Researcheng
dc.titleThe comparative advantage of real options : an explanation for the US specialization in biotechnologyeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record